According to Neurocrine Biosciences 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 7.21012. At the end of 2023 the company had a P/S ratio of 6.86.
Year | P/S ratio | Change |
---|---|---|
2023 | 6.86 | -11.06% |
2022 | 7.71 | 8.2% |
2021 | 7.13 | -16.75% |
2020 | 8.56 | -31.97% |
2019 | 12.6 | -12.4% |
2018 | 14.4 | -66.18% |
2017 | 42.5 | -81.05% |
2016 | 224 | -9.2% |
2015 | 247 | |
2014 | N/A | -100% |
2013 | 216 | 2204.11% |
2012 | 9.35 | 54.16% |
2011 | 6.07 | -51.52% |
2010 | 12.5 | -69.11% |
2009 | 40.5 | 30.41% |
2008 | 31.1 | -78.11% |
2007 | 142 | 1310.15% |
2006 | 10.1 | -46.46% |
2005 | 18.8 | -11.08% |
2004 | 21.1 | 52.7% |
2003 | 13.8 | -82.15% |
2002 | 77.6 | 105.49% |
2001 | 37.8 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Pfizer PFE | 2.80 | -61.20% | ๐บ๐ธ USA |
AbbVie ABBV | 5.32 | -26.15% | ๐บ๐ธ USA |
Eli Lilly LLY | 20.8 | 188.72% | ๐บ๐ธ USA |
Repligen
RGEN | 16.2 | 124.57% | ๐บ๐ธ USA |
Athersys ATHX | 10.4 | 44.45% | ๐บ๐ธ USA |
ANI Pharmaceuticals ANIP | 2.85 | -60.52% | ๐บ๐ธ USA |
Palatin Technologies PTN | 4.75 | -34.19% | ๐บ๐ธ USA |
Royalty Pharma RPRX | 7.24 | 0.37% | ๐ฌ๐ง UK |